MnM Healthcare

  The major factors that are expected to be driving the pharmacy automation market are the growing need to minimize medication errors, rapid decentralization of pharmacies, rising geriatric population and rising labor cost. On the other hand, reluctance among the healthcare organizations to adopt pharmacy automation systems is expected to restrain the overall market growth to a certain extent during the forecast period. What the Market Looks Like? MarketsandMarkets forecasts the  pharmacy automation market  is estimated to grow from USD 3.63 billion in 2017 to USD 5.38 Billion by 2022, at a Compound Annual Growth Rate ( OTC:CAGR ) of 8.2% during the forecast period.  North America is expected to hold the largest market size in the pharmacy automation market during the forecast period, followed by the European region. Medication errors and dispensing errors are recognized as leading causes of hospital readmissions across the globe. A medication error can occur due to a variety of factor

  Compound management is the storage and management of chemical libraries and biosamples used for drug discovery research and clinical purposes. This process comprises multiple steps, including sample acquisition, storage, reformatting, assay plate preparation, and retrieval of a compound/sample. What the Market Looks Like?  The  Compound management market  is projected to reach USD 424.5 million in 2023 from USD 215.3 million in 2018, at a CAGR of 14.5% during the forecast period. The large share of North America is attributed to the presence of the large pharmaceutical and biopharma industry. The growth of the market can be attributed to increasing drug discovery activities, the growing biopharmaceutical industry, and the rising trend in outsourcing compound/sample management. Download PDF Brochure @    https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182172928 What Drives the Market? The growth of the Compound Management Market is primarily influenced by the following factors

 Cervical cancer is the second most common type of cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically proven to be the primary cause of cervical cancer. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens. What the Market Looks Like? The global HPV testing and Pap test market is projected to reach USD 4.52 billion by 2020 from USD 3.29 billion in 2015, at a CAGR of 6.6% from 2015 to 2020. The HPV testing and Pap test market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). However, these tests are unable to detect all the genotypes causing HPV infections and might also lead to a significant number of false negative results. Owing to these challenges posed by Pap tests, HPV diagnostic tests were introduced as effective molecular